Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Griffon Corporation Q2 FY2026 Earnings Call - Clopay Drives Innovation Amid Soft Housing Markets
Griffon Corporation reported steady second-quarter results as it narrows its focus on North American building products following the restructuring of its AMES global businesses into discontinued opera...
- Griffon restructured into a single continuing-operations segment as global AMES businesses are now classified as discontinued operations, with U.S. and Canadian AMES forming a planned joint venture with ONCAP by end of June 2026.
- Second-quarter revenue of $422 million fell 1% year-over-year, driven by a 6% volume decline in soft residential markets, partially offset by 5% price and mix improvements.
- Adjusted EBITDA declined 4% to $98 million, with margin contracting 60 basis points to 23.2% due to higher steel costs and unfavorable overhead absorption from lower volume.
- +7 more takeaways
argenx Q1 2026 Earnings Call - New CEO Karen Massey Sets Vision 2030 on VYVGART Growth and Pipeline Expansion
argenx delivered a robust Q1 2026 with product net sales of $1.3 billion, up 63% year-over-year, driven by strong demand for VYVGART across myasthenia gravis (MG) and chronic inflammatory demyelinatin...
- Product net sales reached $1.3 billion in Q1 2026, representing 63% year-over-year growth, with $1.1 billion from the U.S. market.
- Operating profit rose 183% year-over-year to $394 million, achieving a 30% operating margin and demonstrating clear operating leverage as VYVGART scales.
- New CEO Karen Massey reaffirmed Vision 2030 strategy, targeting 2.5x patient growth on VYVGART and three times more approved indications by 2030.
- +7 more takeaways
Atmos Energy Q2 FY2026 Earnings Call - EPS Guidance Raised to $8.40-$8.50 on Texas Rule 77102 and APT Spread Expansion
Atmos Energy delivered a solid first half of fiscal 2026, with year-to-date net income of $985 million ($5.92 per diluted share), marking a 12.5% year-over-year increase. The company raised its full-y...
- Atmos Energy raised its full-year fiscal 2026 EPS guidance to $8.40-$8.50, up from the previous range of $8.15-$8.35, reflecting stronger-than-expected performance in the first half of the year.
- Year-to-date net income reached $985 million ($5.92 per diluted share), representing a 12.5% increase over the prior year period.
- Texas Rule 77102 implementation is delivering a larger financial benefit than initially projected, with an estimated pre-tax impact of $155 million-$165 million for fiscal 2026, primarily from deferring post-and-service carrying costs, depreciation, and ad valorem taxes.
- +7 more takeaways
Privia Health Q1 2026 Earnings Call - EBITDA Surges 36% as Privia Leverages Strong Cash Flow and AI-Driven Margins to Dominate Value-Based Care
Privia Health delivered a powerful first quarter in 2026, with adjusted EBITDA climbing 36.3% to $36.7 million and care margin expanding 290 basis points to 28.5%. The company added 155 implemented pr...
- Adjusted EBITDA jumped 36.3% year-over-year to $36.7 million, with care margin expanding 290 basis points to 28.5%, highlighting significant operating leverage.
- Implemented provider count grew to 5,535, a 13.6% year-over-year increase, while attributed lives surged 26.5% to 1.6 million, driven by new signings and the Evolent ACO acquisition.
- Management reiterated full-year 2026 guidance, raising the range for attributed lives, and expects EBITDA growth of approximately 20% at the midpoint with 80% conversion to free cash flow.
- +7 more takeaways
Exodus Q1 2026 Earnings Call - Diversifying Revenue Through Monavate and Baanx Acquisitions
Exodus reported a challenging first quarter for its core crypto trading business, with revenue down 37% year-over-year and swap volumes declining 26%. However, the company successfully closed its larg...
- Exodus closed its largest acquisition in company history, integrating Monavate and Baanx to build a full-stack payments infrastructure, marking a strategic shift away from pure crypto reliance.
- Q1 2026 revenue was $22.7 million, a 37% decline year-over-year and a 23% drop from Q4 2025, driven by softer digital asset markets and muted retail trading volumes.
- Swap volume fell 26% to $1.18 billion, while monthly active users remained flat at 1.5 million, and funded users dropped 18% sequentially to $1.4 million.
- +8 more takeaways
Tenaris S.A. Q1 2026 Earnings Call - Middle East Conflict Tests Resilience, North America Offsets
Tenaris reported a resilient Q1 2026, posting $3.1 billion in sales and $564 million in net income. The results were driven by strong North American activity, higher offshore sales in Brazil, and stra...
- New CEO Gabriel Podskubka takes the helm, pledging continuity with outgoing chairman Paolo Rocca and emphasizing a 31-year legacy of operational discipline.
- Q1 sales reached $3.1 billion, up 6% year-over-year and 4% sequentially, proving demand remains robust despite the Strait of Hormuz closure.
- The Middle East conflict disrupted operations, with tenaris expecting a $140 million revenue hit in Q2 as rigs shut down in Kuwait, Qatar, and Iraq.
- +9 more takeaways
Madison Air Q1 2026 Earnings Call - Backlog Surges 116% as IPO Deleveraging Drives Margin Expansion
Madison Air’s first quarter as a public company delivered a clean bill of health for its new management team. Pro forma net sales rose 13% to $924 million, driven by a 41% surge in commercial orders a...
- Record backlog of $2.5 billion, up 116% year-over-year, driven by a 1.4x book-to-bill ratio and strong commercial order momentum.
- Pro forma net sales grew 13% to $924 million, with commercial sales up 18% on a combined basis and residential flat on a combined basis but up 60% reported due to AprilAire.
- Adjusted EBITDA rose 16% to $233 million (implied from 25.3% margin), with margins expanding 70 basis points to 25.3% despite ongoing growth investments.
- +9 more takeaways
Scholar Rock Q1 2026 Earnings Call - FDA Accepts Apitegromab BLA for SMA with Dual Manufacturing Pathways
Scholar Rock has cleared a major regulatory hurdle with the FDA's acceptance of its Biologics License Application for apitegromab, the world's first muscle-targeted therapy for spinal muscular atrophy...
- FDA acceptance of the apitegromab BLA for SMA establishes a PDUFA date of September 30, 2026.
- Scholar Rock included two independent fill-finish facilities in its BLA, providing dual pathways to approval and de-risking the supply chain.
- The FDA completed an unannounced re-inspection of the Catalent, Indiana facility, with a 90-day classification window remaining.
- +8 more takeaways
Phibro Animal Health Corporation Q3 2026 Earnings Call - Sales Surge 10%, Upgraded Guidance, and Brazil Regulatory Transition
Phibro Animal Health delivered a solid third quarter in fiscal 2026, with net sales climbing 10% to $383.5 million and adjusted EBITDA rising 11% to $60 million. The growth was driven by a 13% jump in...
- Net sales increased 10% to $383.5 million, with Animal Health sales up 13% to $291.2 million.
- Adjusted EBITDA rose 11% to $60 million, driven by higher gross profit and strong demand across key segments.
- Full-year fiscal 2026 guidance was raised, with net sales now projected at $1.46B-$1.5B and adjusted EBITDA at $247M-$255M.
- +7 more takeaways
Collegium Pharmaceutical Q1 2026 Earnings Call - AZSTARYS Acquisition Accelerates ADHD Growth Trajectory
Collegium Pharmaceutical delivered a strong first quarter in 2026, driven by double-digit growth in its ADHD franchise and durable cash flows from its pain portfolio. Total net product revenues rose 9...
- JORNAY PM net revenue surged 36% year-over-year to $38.9 million, with prescriptions growing 14% and prescriber count hitting a record 30,000.
- Total net product revenues reached $193.5 million, up 9% year-over-year, with adjusted EBITDA rising 9% to $103.9 million.
- The pain portfolio generated $154.6 million in revenue, up 4%, driven by price increases and gross-to-net benefits that offset seasonal volume pressure.
- +7 more takeaways